Clinical Trial Update: Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical study of anti-CD1a CAR-T for relapsed/refractory acute T-lymphoblastic leukemia and lymphoblastic lymphoma is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-lymphoblastic Leukemia
• T-lymphoblastic Lymphoma

Drugs mentioned

• Anti-CD1a CAR-T (CD1a-targeted chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: The Affiliated Hospital of Xuzhou Medical University | Conditions: Acute T-lymphoblastic Leukemia, Acute T-lymphoblastic Lymphoma | Phase 2 | Status: UNKNOWN